Professor Sangyong Jon’s group has developed an organ-selective drug delivery platform based on a library of glycocalyx-mimicking nanoparticles (GlyNPs). Direct in vivo library screening enables identification of GlyNP hits targeting the liver, spleen, lung, kidneys, heart, and brain. When liver-, kidney-, and spleen-selective GlyNP hits are equipped with therapeutics, the formulations effectively alleviated symptoms in organ-associated disease models....read more
A new class of photonic nanomaterial with biodegradability and biocompatibility is developed for combined photoacoustic imaging and photothermal therapy of cancers....read more